Ramantamig plus daratumumab for untreated multiple myeloma without stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of two drugs, ramantamig and daratumumab, against other standard treatments for people newly diagnosed with multiple myeloma who are not planning to have a stem cell transplant. The goal is to see if this combination works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma.
- You are not planning to have a stem cell transplant, either because of age or other health conditions.
- Your daily activity level is mostly normal (you can care for yourself, though you may need some help).
- You have not had treatment for multiple myeloma before, except possibly a short course of steroids in an emergency.
- You are not considered frail, unless frailty is only due to age.
- You do not have any known allergies to the study drugs or their ingredients.
- You have not had major surgery or serious injury in the past 2 weeks, and you do not have any planned during the trial.
- You do not have multiple myeloma that has spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This trial is testing a new combination of drugs for people with untreated multiple myeloma who are healthy enough for a stem cell transplant. It aims to see if the treatment is safe and effective.
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
This trial tests two different drug combinations for people newly diagnosed with multiple myeloma who are not getting a stem cell transplant right away. It compares one drug (elranatamab) to another (daratumumab), both given with a standard three-drug regimen called RVd Lite, to see which works better.
This trial studies elranatamab (alone and combined with daratumumab) in people with multiple myeloma who have already received other treatments, including lenalidomide. It aims to see how well these medicines control the cancer and what side effects people experience.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.